Last reviewed · How we verify

Abrupt cessation of phentermine pharmacotherapy

Center for Weight Management, California · Phase 1 active Small molecule

Abrupt cessation of phentermine pharmacotherapy is a Small molecule drug developed by Center for Weight Management, California. It is currently in Phase 1 development. Also known as: Phentermine-HCL, generic.

At a glance

Generic nameAbrupt cessation of phentermine pharmacotherapy
Also known asPhentermine-HCL, generic
SponsorCenter for Weight Management, California
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Abrupt cessation of phentermine pharmacotherapy

What is Abrupt cessation of phentermine pharmacotherapy?

Abrupt cessation of phentermine pharmacotherapy is a Small molecule drug developed by Center for Weight Management, California.

Who makes Abrupt cessation of phentermine pharmacotherapy?

Abrupt cessation of phentermine pharmacotherapy is developed by Center for Weight Management, California (see full Center for Weight Management, California pipeline at /company/center-for-weight-management-california).

Is Abrupt cessation of phentermine pharmacotherapy also known as anything else?

Abrupt cessation of phentermine pharmacotherapy is also known as Phentermine-HCL, generic.

What development phase is Abrupt cessation of phentermine pharmacotherapy in?

Abrupt cessation of phentermine pharmacotherapy is in Phase 1.

Related